Trials with a site in Zagreb, Croatia

This is a Phase 3, multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study to measure the clinical how well it works, safety, and tolerability of XEN1101 administered as added on top of your current treatment treatment in primary generalized tonic-clonic seizures (PGTCS).

NCT05667142 · Official ClinicalTrials.gov record · Xenon Pharmaceuticals Inc.

This study aims to compare the how well it works of vericiguat versus dummy treatment (placebo) on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to dummy treatment (placebo) in reducing NT-proBNP at Week 16 of the Base Period.

NCT05714085 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

The X-TOLE3 Phase 3 clinical trial is a randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study that will measure the clinical how well it works, whether it is safe and how hard side effects are to live with of XEN1101 administered as added on top of your current treatment therapy in focal-onset seizures.

NCT05716100 · Official ClinicalTrials.gov record · Xenon Pharmaceuticals Inc.

This is a Phase 2, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, multicenter study to measure the how well it works and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).

NCT06226883 · Official ClinicalTrials.gov record · Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections \[SC\]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of assessments that rate the severity and extent of atopic dermatitis and its symptoms, as well as general health status and quality of life.

NCT06311682 · Official ClinicalTrials.gov record · LEO Pharma

The purpose of this protocol is to measure the how well it works and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to dummy treatment (placebo) in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 52 (US/FDA and EU/EMA), and that at least 1 tulisokibart dose level is superior to dummy treatment (placebo) in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA).

NCT06430801 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

This is a multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, parallel-group, compared with a dummy treatment, flexible-dose study evaluating the how well it works, safety, and tolerability of ITI-1284 compared with dummy treatment (placebo) in the treatment of psychosis in patients with AD.

NCT06540833 · Official ClinicalTrials.gov record · Intra-Cellular Therapies, Inc.

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss.

NCT06548542 · Official ClinicalTrials.gov record · AbbVie

This study wants to measure the safety and how well it works of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

NCT06585787 · Official ClinicalTrials.gov record · Karuna Therapeutics, Inc., a Bristol Myers Squibb company

The Phase 1 study described herein will measure the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).

NCT06619990 · Official ClinicalTrials.gov record · Xencor, Inc.

This is a multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, flexible-dose study of the how well it works, safety, and tolerability of ITI-1284 in patients with agitation associated with Alzheimer's dementia.

NCT06651567 · Official ClinicalTrials.gov record · Intra-Cellular Therapies, Inc.

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs.

NCT06671483 · Official ClinicalTrials.gov record · Takeda

This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I) The primary objective of the study is to measure the long-term whether it is safe and how hard side effects are to live with of KarXT in the treatment of participants with mania or mania with mixed features associated with BP-I.

NCT06929273 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

This is a Phase 3, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, multicenter, inpatient study in participants with bipolar disorder experiencing an acute episode of mania or mania with mixed features. The primary objective of the study is to measure the how well it works of KarXT compared to dummy treatment (placebo) in treating symptoms of mania during a 3-week inpatient period.

NCT06951711 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. this study wants to assess how safe and effective Surabgene Lomparvovec is in treating participants with Neovascular age-related macular degeneration (nAMD).

NCT07007065 · Official ClinicalTrials.gov record · AbbVie

This study wants to measure the how well it works and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

NCT07011732 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure.

NCT07064473 · Official ClinicalTrials.gov record · Boehringer Ingelheim

Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomly assigned, neither you nor the study doctors know who gets the real treatment, parallel-group, multicenter study to measure the how well it works and safety of orelabrutinib compared with dummy treatment (placebo) in patients with PPMS.

NCT07067463 · Official ClinicalTrials.gov record · Zenas BioPharma (USA), LLC

The objective of this study is to assess the potential for GB-0895 to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. Additional information is available at www.SOLAIRIA.com.

NCT07276724 · Official ClinicalTrials.gov record · Generate Biomedicines

Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomly assigned, neither you nor the study doctors know who gets the real treatment, parallel-group, multicenter study to measure the how well it works and safety of orelabrutinib compared with dummy treatment (placebo) in patients with non-active Secondary Progress MS.

NCT07299019 · Official ClinicalTrials.gov record · Zenas BioPharma (USA), LLC

The OPTION-EMEA post-market study is intended to gather real world clinical data for patients undergoing AF ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent left atrial appendage closure (LAAC) with a WATCHMAN FLX™ Pro or WATCHMAN FLX device during one treatment case. The study will include patients that are clinically indicated for atrial fibrillation (AF) ablation using the FARAPULSE PFA System and for left atrial appendage closure (LAAC) treatment using a WATCHMAN FLX Pro or WATCHMAN FLX device as part of the patient's standard of care determined by their doctor's medical judgement.

NCT07349121 · Official ClinicalTrials.gov record · Boston Scientific Corporation

This study is open to adults with systemic lupus erythematosus (SLE). this study wants to find out whether a medicine called BI 3000202 helps people with SLE.

NCT07409181 · Official ClinicalTrials.gov record · Boehringer Ingelheim

The main purpose of this study is to measure the safety and effectiveness of LY4268989 when compared to dummy treatment (placebo) in adult participants with moderately to severely active ulcerative colitis (UC). The study drug will be administered orally.

NCT07415044 · Official ClinicalTrials.gov record · Eli Lilly and Company

This is a randomly assigned, Phase 3 trial designed to measure the how well it works and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expression.

NCT07546500 · Official ClinicalTrials.gov record · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc